len

working with software / hardware / biology on distributed bio @ global scale.

[len @len_unofficial]

@jrkelly including dna cost?

[len @len_unofficial]

statistics are fine. the risk is that the underlying assumptions - often made decades earlier - are incorrect.

eg microbial production of biofilm is root cause which becomes a scaffold to adhere & aggregate on - all starting with access to the bloodstream from oral disease/lesions in the mouth.

[len @len_unofficial]

@jrkelly @Ginkgo human-like glycosylation next?!

[len @len_unofficial]

@LongmireMD @healthspanmed ooo is topical version encapsulated or just formulated in some hydrogel?

[len @len_unofficial]

@ImmunoFever @raflynn5 local & focus on protein expression

[len @len_unofficial]

@eperlste @letUbeU working on this, happy to chat

[Prof Peter Hotez MD PhD DSc(hon) @PeterHotez]

I think our patent-free @TexasChildrens recombinant protein Covid vaccine technology, 100 million doses administered in India 🇮🇳 and Indonesia around $2-3 per dose, roughly

[len @len_unofficial]

@dwidmaier would argue the misappropriation of attention/resources/etc for land-based solutions instead of ocean-based is primary with scaling being next

[len @len_unofficial]

@jrkelly @BursatilBiotech seconded. hard assets are more real than projections of scientific/industrial production, which makes for a great default for startups.

also, few understand the fragility at the early stage & how amazing a network that helps reduce overhead is - eg with resources like space.

[len @len_unofficial]

@SidAthreya @MaxxChatsko doing well from the consumer side, have heard opinions that the branding direction + sephora have been limiting for their wider appeal, marketing spend seems to drown out any kind of viable economics or sanity

[len @len_unofficial]

@MaxxChatsko @p_maverick_b number of efforts to expand our production organisms out there but as always legacy/experience/labor drives a lot of industrial choices

[len @len_unofficial]

@p_maverick_b @MaxxChatsko +1 - easier to work with [eg secretion -> simpler dsp], human-like glycosylation [therapeuatics, antibodies]

[len @len_unofficial]

@JamesPeyer @OpenAI curious to see the response to "why is aging a disease?" 🙃

[len @len_unofficial]

@elkingtonxy these are synbio startup ceos - similar to early stage tech ceos being pms - but the regulatory/pharma influence is limiting the breadth of creation :/

[Phil Renforth @phil_renforth]

Our paper on a roadmap for geochem. CDR is out in Frontiers in Climate. @DrMaesano and James Campbell contributions from @RCCS (Veronica Furey, Spyros Foteinis @olivia_hawrot ) @PaulReginato @D_R_Goodwin @LoogerL @eboyden3 Daniel Pike Silvan Aeschlimann
https://t.co/jRVVu4gPEG

[len @len_unofficial]

@LongmireMD @medableinc would love to partner here - best way to connect?

[len @len_unofficial]

@LoogerL @neuroclef @PaulReginato afaik this is where the market-based approach is failing!

the capex/opex to start production are prohibitive & marginal improvements wont give you an easy market entry point

likely need to start with higher value products rather than commodity chemicals

[len @len_unofficial]

@ZHallberg @tony_burnetti @SamWitus @HoorayForZinder naturally higher protein expression, secretion simplifies downstream as opposed to lysing e.coli

in some cases, glycosylation

[len @len_unofficial]

@ZHallberg @tony_burnetti @SamWitus @HoorayForZinder not too hard

would opt for pichia tho

also would use a fusion protein to enhance expression out of the gate

[len @len_unofficial]

@PSU_EcoliRefCtr @sciliz @JPox14 @microdudley id like to see distributed storage of characterized strains happen across fields - eg building a library of yeast strains producing high value protein products

i would offer my -80c storage capacity